This inventor holds 30 USPTO granted patents and 27 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Oligonucleotide Compositions. Top assignees: Molecular Insight Pharmaceuticals, Inc., Wave Life Sciences Ltd., Cumbre IP Ventures, L.p.. Active years: 2010-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Plano, TX (US) (2010)
- Winchester, MA (US) (2010 - 2023)
Company Filing History:
16 out of 41 
11 out of 41 
1 out of 2 
Years Active: 2010-2026
Areas of Expertise:
Title: Innovations and Contributions of Genliang Lu in Oligonucleotide Research
Introduction
Genliang Lu, based in Winchester, MA, has made significant contributions to the field of oligonucleotide research, holding an impressive 25 patents. His work primarily focuses on the synthesis and application of oligonucleotides, which are crucial in the treatment of genetic disorders, particularly those related to the C9orf72 gene.
Latest Patents
Among his latest patents, Genliang Lu has developed compositions and methods involving oligonucleotides. These innovations encompass various structural elements, such as base sequences and chemical modifications, which greatly influence the properties and activities of oligonucleotides. For instance, some oligonucleotides he designed are aimed at decreasing the expression of the C9orf72 gene, especially those with repeat expansions, thereby offering potential treatment options for C9orf72-related disorders. Furthermore, he has also patented technologies related to synthesis, providing methods for stereoselective synthesis and improved oligonucleotide preparation.
Career Highlights
Throughout his career, Genliang Lu has contributed to notable companies, including Molecular Insight Pharmaceuticals, Inc. and Wave Life Sciences Ltd. His expertise in oligonucleotide technology has positioned him as a key innovator in the biotechnology space, focusing on creating efficient and effective solutions for complex genetic challenges.
Collaborations
In his professional journey, Genliang has collaborated with esteemed colleagues like John W. Babich and Craig N. Zimmerman. Their collective efforts have further advanced the field of oligonucleotide research and expanded the horizons of genetic therapeutic approaches.
Conclusion
Genliang Lu continues to be a pioneering figure in the development of oligonucleotide technologies, with a focus on improving treatment methods for genetic disorders. His extensive patent portfolio highlights his innovative spirit and commitment to advancing the field of molecular biology. As research in this area progresses, the impact of his work is expected to resonate deeply within the scientific community and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile